Compare AIRS & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | ANIK |
|---|---|---|
| Founded | 2012 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 191.4M |
| IPO Year | 2021 | 1996 |
| Metric | AIRS | ANIK |
|---|---|---|
| Price | $2.73 | $15.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 2.2M | 111.6K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $151,818,000.00 | $112,819,000.00 |
| Revenue This Year | $5.30 | $5.98 |
| Revenue Next Year | $6.49 | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $7.90 |
| 52 Week High | $12.00 | $15.48 |
| Indicator | AIRS | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 66.12 |
| Support Level | $2.52 | $13.81 |
| Resistance Level | $3.36 | N/A |
| Average True Range (ATR) | 0.36 | 0.55 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 34.78 | 89.52 |
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.